Sera Prognostics (NASDAQ:SERA – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Sera Prognostics and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Monte Rosa Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 169.61%. Monte Rosa Therapeutics has a consensus target price of $26.67, suggesting a potential upside of 147.83%. Given Sera Prognostics’ higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Monte Rosa Therapeutics.
Valuation and Earnings
This table compares Sera Prognostics and Monte Rosa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,005.98 | -$31.93 million | ($0.67) | -3.04 |
| Monte Rosa Therapeutics | $123.67 million | 7.42 | -$38.63 million | ($1.76) | -6.11 |
Sera Prognostics has higher earnings, but lower revenue than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Sera Prognostics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Insider and Institutional Ownership
54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Sera Prognostics and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Summary
Monte Rosa Therapeutics beats Sera Prognostics on 8 of the 14 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
